The Danish pharmaceutical company Novo Nordisk has announced a strategic partnership with OpenAI to accelerate the development of new treatments. The goal is to leverage artificial intelligence to reduce the time between research and the availability of therapeutic solutions.
The group, known particularly for its diabetes and obesity medications, aims to leverage AI to analyze vast datasets and identify promising candidates more quickly. This approach should improve the efficiency of research processes in a sector where bringing a drug to market can take more than ten years.
An innovation strategy in the face of increased competition
Pilot programs will be launched in several areas, including research, production and commercial activities, with gradual integration planned by the end of 2026. No financial details have been released on this agreement.
This partnership is part of a broader trend in the pharmaceutical industry, which is investing heavily in artificial intelligence to reduce development costs and time. Novo Nordisk operates in a more competitive environment, particularly against groups like Eli Lilly.
Community
Comments
Comments are open, but protected against spam. Initial posts and comments containing links undergo manual review.
Be the first to comment on this article.